Join medical device and digital health entrepreneurs, CEOs of venture-backed companies, and business development executives from large Medtech and digital health companies, as well as angels, venture capitalists, and...more
5/8/2025
/ Acquisitions ,
Antitrust Violations ,
Artificial Intelligence ,
CEOs ,
Digital Health ,
Emerging Growth Companies ,
Equity Compensation ,
Events ,
Executive Compensation ,
Exit Strategies ,
Food and Drug Administration (FDA) ,
Innovation ,
Investors ,
Med Tech ,
Medical Devices ,
Mergers ,
Patents ,
Startups ,
Venture Capital
DOJ's Most Recent Monopolization Case Reflects Several Agency Priorities Including Expansion of Section 2 to Respond to Headline-Grabbing Popular Demands...more
The Federal Trade Commission’s suit alleging U.S. Anesthesia Partners (USAP) and Welsh Carson, a private equity fund that owns 23 percent of USAP and controls two of 14 board seats, engaged in an anticompetitive scheme to...more
On June 30, 2023, a jury in the Northern District of California found Gilead and Teva not liable in a trial accusing the companies of engaging in an illegal reverse payment to delay generic versions of two HIV drugs, Truvada...more
7/6/2023
/ Anti-Competitive ,
Antitrust Litigation ,
Antitrust Violations ,
Generic Drugs ,
HIV ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Reverse Payments
Wilson Sonsini provides extensive and cutting-edge legal services for innovators, technology pioneers, and disruptors. As part of our focus on emerging technologies, our attorneys are publishing a series on applying and...more
Wilson Sonsini is pleased to present the latest edition of The Life Sciences Report. This issue features an interview with Foresight Diagnostics co-founder and CEO Jake Chabon conducted by Matthew Meyer, the firm’s Chief...more